1.. Introduction
================

Rising levels of bacterial multidrug resistance are an increasing problem in the treatment of infectious diseases. This phenotype is often associated with the expression of multidrug efflux (MDE) transporters, which export drugs out of the cell. The involved proteins belong to five well-characterized families: the ATP-binding cassette (ABC) family, the major facilitator superfamily (MFS), the resistance-nodulation-cell division (RND) superfamily, the small multidrug resistance (SMR) family, and the multidrug and toxic compound extrusion (MATE) family \[[@b1-ijms-10-00629]\]. Efflux by transporters of the MFS, RND, SMR, and MATE families is driven by proton (or sodium) motive force while ATP hydrolysis drives efflux in ABC transporters \[[@b2-ijms-10-00629]--[@b5-ijms-10-00629]\].

RND-type transporters are widespread in Gram negative bacteria. In these efflux pumps, an outer membrane protein of the TolC family co-operates with both, an energized inner membrane translocase typically comprising a proton anti-porter and an adaptor protein located in the periplasmic space, thus forming a tripartite efflux system \[[@b2-ijms-10-00629],[@b4-ijms-10-00629]\]. A remarkable feature of these efflux systems is the wide range of substrates that are recognized by individual pumps \[[@b6-ijms-10-00629]--[@b7-ijms-10-00629]\].

*Escherichia coli*, a member of *Enterobacteriaceae*, is one of the best and most thoroughly studied bacterial species. Some *E. coli* strains live as harmless commensals in the human intestines while other strains are pathogenic causing diseases and high mortality in humans \[[@b8-ijms-10-00629]\]. AcrAB-TolC of *E. coli* is the best characterized RND efflux pump and has emerged as the principal structural and biochemical model system. The anti-porter AcrB and the membrane fusion adaptor AcrA form a translocase unit that interacts with the outer membrane protein TolC thus comprising a contiguous protein complex spanning the bacterial cell envelope and enabling drug efflux \[[@b9-ijms-10-00629]--[@b10-ijms-10-00629]\].

AcrAB-TolC mediates resistance towards a wide variety of hydrophobic and amphiphilic compounds including bile salt, detergents, dyes, and antimicrobial agents \[[@b10-ijms-10-00629]\]. Respective alleles of different gram-negative bacteria show a high degree of similarity and their deduced amino acid sequences are homologous \[[@b11-ijms-10-00629]--[@b12-ijms-10-00629]\]. The *acrAB* loci are regulated by members of TetR family of transcriptional repressors named AcrR. The *acrR* gene is located 141 bp upstream of the *acrAB* locus and is divergently transcribed \[[@b13-ijms-10-00629]\]. AcrB is of particular interest since it mediates substrate specificity of the tripartite MDE pump towards a wide range of structurally diverse substances \[[@b14-ijms-10-00629]\]. AcrAB recruits the separately expressed outer membrane protein TolC to extrude substrates from the inner membrane or the cytoplasm without any substrate accumulation in the periplasmic space \[[@b15-ijms-10-00629]\].

Homologues of *E. coli* TolC have been identified in numerous Gram-negative bacteria. Different AcrAB-like transport systems have evolved in *E. coli* and all share TolC as outer membrane partner \[[@b16-ijms-10-00629]--[@b18-ijms-10-00629]\]. The same was found for *Klebsiella pneumoniae* where AcrAB homologues specifically interact with the TolC-like outer membrane protein KocC, and the respective genes are not co-transcribed \[[@b19-ijms-10-00629]\]. In contrast, in other gram-negative bacteria individual TolC-like channels are often unique for a given RND-type transporter and their genes are consequently co-expressed in the same gene cluster as the RND-type pumps such as in the case of the *oprJMN* cluster in *Pseudomonas aeruginosa* \[[@b20-ijms-10-00629]--[@b21-ijms-10-00629]\] or the *mtrRCDE* cluster in *Neisseria gonorrhoeae* \[[@b22-ijms-10-00629]\]. In bacterial species other than *E. coli*, the functions attributed to TolC are not linked to a single *tolC* allele but are distributed among various *tolC* homologues \[[@b23-ijms-10-00629]\].

Comparative genome analyses revealed high numbers of MDE pumps in soil or plant-associated bacteria \[[@b24-ijms-10-00629]\]. Plants produce an array of diverse secondary metabolites that have antimicrobial activities including preformed so-called phyto-anticipants and phytoalexins, which are synthesized in response to pathogen attack \[[@b25-ijms-10-00629]--[@b26-ijms-10-00629]\]. An increasing number of RND-type transporters conferring multidrug resistance in plant-associated bacteria have recently been identified, for examples in *Agrobacterium tumefaciens* \[[@b27-ijms-10-00629]\], in *Pseudomonas syringae* \[[@b28-ijms-10-00629]\], in *Erwinia chrysanthemi* \[[@b29-ijms-10-00629]\], in *Bradyrhizobium japonicum* \[[@b30-ijms-10-00629]\], in *Xanthomonas oryzae* \[[@b31-ijms-10-00629]\], and in *Ralstonia solanacearum*\[[@b32-ijms-10-00629]\].

*E. amylovora*, a member of *Enterobacteriaceae,* is the causal agent of fire blight on apple and various other *Rosaceae*. Burse *et al*. \[[@b33-ijms-10-00629]\] demonstrated that AcrB played an important role in virulence of *E. amylovora* and was required for resistance towards diverse plant phytoalexins as well as for successful colonization of the host plant. Recently, mutational analysis showed that TolC is also indispensable for virulence and bacterial *in planta* multiplication by mediating resistance towards phytoalexins through its exclusive interaction with AcrAB in *E. amylovora* \[[@b34-ijms-10-00629]\].

Herein, knock-out mutants of *E. amylovora* and *E. coli* defective in *acrAB* or *tolC*, respectively, were complemented with respective homologous or heterologous alleles in order to investigate whether components of the two systems can be exchanged thereby altering substrate spectra and to determine potential ecological niche-mediated adaptations for both bacterial species.

2.. Results and Discussion
==========================

2.1.. Bioinformatics approach
-----------------------------

A BLAST search with the genome sequence of *E. amylovora* Ea237 (<http://www.sanger.ac.uk/projects/E.amylovora>) using the amino acid sequence of AcrB from *E. coli* K12 strain DH10B (accession number YP-001729367) as query identified six homologous sequences in the genome of Ea237. At the amino acid sequence level, the respective predicted *E. amylovora* proteins showed the following identities (similarities given in brackets): AcrB with 83% (92%), AcrD with 78% (89%), MdtB with 81% (90%), MdtC with 73% (86%), and two MdtB- and MdtC-like proteins with 63% (79%) and 56% (73%), respectively \[[@b35-ijms-10-00629]--[@b36-ijms-10-00629]\].

Additionally, the respective *E. amylovora* homologues of the *E. coli* membrane fusion protein AcrA and the transcriptional repressor AcrR showed 73% and 62% identity (83% and 79% similarity), respectively \[[@b13-ijms-10-00629],[@b35-ijms-10-00629]\]. A BLAST search using the amino acid sequence of TolC from *E. coli* revealed presence of only one TolC homologue in *E. amylovora* with 77% identity (86% similarity) suggesting a high degree of conservation of genomic arrangements between the two enterobacterial species.

2.2.. Susceptibility of E. coli and E. amylovora towards antimicrobial compounds
--------------------------------------------------------------------------------

The susceptibility of the wild types and respective single mutants with deletions in *acrB* or *tolC* of *E. coli* and *E. amylovora* to a variety of antimicrobial compounds were examined in complex and minimal medium using the determination of minimal inhibitory concentrations (MIC) ([Tables 1](#t1-ijms-10-00629){ref-type="table"}--[4](#t4-ijms-10-00629){ref-type="table"}). Double mutants defective in *acrB* and *tolC* served as negative controls. Different plant-derived antimicrobial compounds, which were previously reported to be substrates for *E. amylovora* AcrAB-TolC \[[@b33-ijms-10-00629]--[@b34-ijms-10-00629]\], bile salt as a reported substrate for AcrAB-TolC in *E. coli* \[[@b37-ijms-10-00629]\], and various other antimicrobials were tested. Single deletion of *acrB* or *tolC* and simultaneous deletion of *acrB* and *tolC* resulted in increased susceptibility of *E. coli* mutants toward all tested plant-borne antimicrobial compounds. The respective MICs for phloretin, (+)-catechin, naringenin, quercetin, and berberine decreased more than 4-fold, 4-fold, 8-fold, 8-fold, and 16-fold, respectively, in complex medium and about 8-fold in minimal medium except for berberine, for which the MICs were reduced about 64-fold, as compared to *E. coli* wild type MICs ([Tables 1](#t1-ijms-10-00629){ref-type="table"} and [3](#t3-ijms-10-00629){ref-type="table"}). Similarly, *E. amylovora* mutants defective in *acrB* or *tolC* and the double mutant exhibited 4-fold, 8-fold, 8-fold, 16-fold, and 32-fold decreased MICs towards (+)-catechin, phloretin, naringenin, quercetin, and berberine, respectively, in both, complex and minimal medium ([Tables 2](#t2-ijms-10-00629){ref-type="table"} and [4](#t4-ijms-10-00629){ref-type="table"}). Consequently and despite of the fact that *E. coli* is neither a plant pathogen nor usually exposed to plant-borne chemical defense reactions, AcrAB-TolC of this human-associated bacterium can exclude phytoalexins. This interesting result further substantiated the broad substrate spectrum of this MDE system \[[@b14-ijms-10-00629],[@b38-ijms-10-00629]\] and is in line with the idea that intestinal microbes are constantly challenged by toxic substances derived from plant-borne diet in mammals \[[@b39-ijms-10-00629]\]. Alternatively, our result might indicate a high degree of phylogenetically conserved functionality of the AcrAB-TolC complex among *enterobacteriaceae*.

The three tested *E. amylovora* mutants were about 8-fold more sensitive to bile salt as compared to the wild type regardless of the used medium. In contrast, the three *E. coli* mutants exhibited a 64-fold increased sensitivity to bile salt in both media in comparison to the wild type ([Tables 1](#t1-ijms-10-00629){ref-type="table"}--[4](#t4-ijms-10-00629){ref-type="table"}). This result clearly demonstrated that *E. amylovora* may possess an alternative MDE pump during the detoxification process for bile salts such as demonstrated for EefABC in *Enterobacter aerogenes* \[[@b40-ijms-10-00629]\]. It remained obscure why the *E. coli* mutants exhibited higher susceptibilities towards bile salt since one might have assumed a better adaptation of this bacterium to this toxic compound \[[@b41-ijms-10-00629]\].

In contrast to the mutants of *E. amylovora*, growth medium-dependent susceptibility towards the following group of antimicrobials was observed for the three *E. coli* mutants: acriflavine, novobiocin, ampicillin, cefoperazone, mitomycin, tetracycline, nalidixic acid, norfloxacin, ciprofloxacin, SDS, ethidium bromide, and crystal violet. For those substances the *E. coli* wild type was about 5- to 20-fold more resistant as compared to the mutants in complex medium but only 4- to 10-fold more resistant in minimal medium ([Tables 1](#t1-ijms-10-00629){ref-type="table"} and [3](#t3-ijms-10-00629){ref-type="table"}). *E. amylovora* mutants were 5- to 40-fold more sensitive to those compounds as compared to their wild type regardless of the used growth medium ([Tables 2](#t2-ijms-10-00629){ref-type="table"} and [4](#t4-ijms-10-00629){ref-type="table"}). These apparently conflicting results might be rather due to the auxotropic status of *E. coli* TG1 and its general physiological fitness in minimal medium \[[@b42-ijms-10-00629]\] than due to substrate specificity alterations.

The MICs of the aminoglycosides amikacin and tobramycin for the *acrB* mutants of *E. coli* and *E. amylovora* did not differ from those determined for the wild type strains suggesting that those substances did not act as substrates of AcrB. In contrast, the same substances caused 8-fold and 16-fold increased sensitivities for the *tolC* mutants and the *acrB* / *tolC* double mutants of both species in complex and minimal medium, respectively. It was previously demonstrated that TolC additionally to its function with AcrB could specifically interact with another RND-type transporter of *E. coli* termed AcrAD in extruding a variety of hydrophilic aminoglycosides from the periplasm and cytoplasm \[[@b38-ijms-10-00629],[@b43-ijms-10-00629]\].

Additive effects in the reduction of MICs due to simultaneous disruption of *acrB* and *tolC* regardless of the used species and medium could be observed for erythromycin, rifampin, jasmone, and clotrimazole. The MIC values of the *acrB* mutants for these compounds were reduced 4- to 10-fold. In contrast, respective MIC values declined in the *tolC* mutants about 10- to 40-fold. Susceptibilities increased 64- to 200-fold in the *acrB* / *tolC* double mutant of *E. coli* and about 80-fold in the respective *E. amylovora* double mutant ([Tables 1](#t1-ijms-10-00629){ref-type="table"}--[4](#t4-ijms-10-00629){ref-type="table"}), suggesting that outer membrane-bound TolC might interact with additional partners during the extrusion of these compounds. Chollet *et al*. \[[@b44-ijms-10-00629]\] demonstrated that telithromycin, a ketolide comparable to macrolides, is not a substrate for AcrAB-TolC but it is efficiently recognized by another PAβN-sensitive system pump. Elkins and Mullis \[[@b14-ijms-10-00629]\] showed that the MFS-type tripartite system, EmrAB-TolC, of *E. coli* has the extraordinary capacity to transport mammalian steroid hormones. This transporter is 'silent' under normal laboratory conditions and its contribution to MDE resistance towards steroids and macrolides is masked by the overlapping substrate repertoire of the AcrAB-TolC system \[[@b14-ijms-10-00629]\]. Likewise, MacAB of *E. coli* is cooperating with TolC in exporting macrolides \[[@b45-ijms-10-00629]\]. The herein observed additive effects in MIC reduction may be related to presence of EmrAB in both, *E. coli* and *E. amylovora*. A BLAST search in the genome sequence of *E. amylovora* 237 revealed presence of an EmrB homolog with 83% identity and 92% similarity but no MacB homologs.

2.3.. Allelic exchange analysis of AcrAB-TolC in E. amylovora and E. coli
-------------------------------------------------------------------------

As expected and in line with our previously published data \[[@b33-ijms-10-00629]--[@b34-ijms-10-00629]\], the MIC phenotypes of *acrB* and *tolC* single mutants of *E. amylovora* could be fully restored to wild type levels with clones containing *E. amylovora acrAB* and *tolC*, respectively. Without any exceptions, the same results were obtained when respective *E. coli* mutants were complemented with cloned *E. coli acrAB* and *tolC* genes ([Tables 1](#t1-ijms-10-00629){ref-type="table"}--[4](#t4-ijms-10-00629){ref-type="table"}). Next, single mutants of *E. amylovora* were transformed to carry *acrAB* or *tolC*, respectively, derived from *E. coli* and vice versa. Thus it was tested whether or not the individual components of the AcrAB-TolC complex from the two enterobacterial species can interact without interferences. Interestingly, all thus generated transformants showed fully restored wild type MIC phenotypes ([Tables 1](#t1-ijms-10-00629){ref-type="table"}--[4](#t4-ijms-10-00629){ref-type="table"}), suggesting that the AcrAB-TolC efflux systems of *E. coli* and *E. amylovora* are truly interchangeable despite of the variable ecological niches both organisms occupy. The results furthermore allowed the conclusion that the divergence in micro-ecological adaptation had not led to specialized MDE pumps with respect to AcrAB-TolC but that this system is multifunctional and ancestral. This confirmed an earlier study, in which MDE pumps from *Ralstonia solanacearum* were used to complement respective *E. coli* mutants \[[@b32-ijms-10-00629]\]. Our data are also in agreement with those from Tikhonova *et al.* \[[@b46-ijms-10-00629]\] and Bokma *et al*. \[[@b47-ijms-10-00629]\], who reported on the functionality of AcrB-MexB hybrid proteins and the directed evolution-based adaptation of *E. coli* TolC to the MexAB translocase of *Pseudomonas aeruginosa*. The later authors generated active hybrid pumps by challenging a library of mutated and shuffled TolC variants to adapt to the non-cognate *P. aeruginosa* MexAB system. The obtained analysis of amino acid substitutions in TolC revealed that adaptation to the heterogenous efflux pump was conferred by substitutions of amino acyl residues located in the lower α-helical barrel in the periplasmic equatorial domain and the entrance coiled coils of TolC \[[@b47-ijms-10-00629]\]. Protein sequence alignment of *E. coli* TolC versus that of *E. amylovora* TolC revealed that all the substituted amino acid residues reported by Bokma *et al*. \[[@b47-ijms-10-00629]\] are conserved in both enterobacterial species (data not shown) thus by further substantiating a tight phylogenetic relatedness of AcrAB-TolC in *E. coli* and *E. amylovora*.

Interestingly, any complementation led to MIC wild type level of the species, into which the heterologous alleles were transferred. These results underscore the principle that antibiotics resistance is determined by both, efflux and outer membrane permeability. In this context, it is remarkable that permeability for many of the tested compounds differed between *E. amylovora* and *E. coli*.

2.4.. In planta virulence assays
--------------------------------

Previously it was demonstrated that *E. amylovora* mutants with defects in *acrB* and *tolC* were not causing fire blight symptoms on apple plants and showed significantly reduced *in planta* survival \[[@b33-ijms-10-00629]--[@b34-ijms-10-00629]\]. These mutants could be complemented by plasmid-borne homogenous alleles. Since heterogenous alleles of *acrB* and *tolC* led to wild type MIC values in the respective *E. amylovora* mutants *in vitro*, it was tested whether *acrB* and *tolC* of *E. coli* could restore virulence of *E. amylovora acrB* and *tolC* single mutants. Respective *E. amylovora* transformants were inoculated to apple plants using the mutants and the wild type as controls. Plant shoot tips were inoculated with defined numbers of bacterial cells by the so-called prick technique \[[@b48-ijms-10-00629]\], which mimics the natural infection process. Typical fire blight symptoms in form of shepherd's crook-like bending of the shoot tip after one week post inoculation as well as ooze formation and necrosis after three weeks post inoculation were induced by *E. amylovora* wild type and the *E. amylovora* mutants carrying *acrB* or *tolC* from *E. coli* in all 15 plants inoculated per strain without exceptions ([Figure 1](#f1-ijms-10-00629){ref-type="fig"}).

In contrast, the non-complemented mutants did not cause any disease symptoms thus confirming their previously reported *in planta* phenotypes \[[@b33-ijms-10-00629]--[@b34-ijms-10-00629]\]. All inoculated plants showed the same lack of symptom development. Interestingly, for the first time these results led to the conclusion that enterobacterial AcrAB-TolC hybrids consisting of mixed components from a plant pathogen and an intestinal species are sufficient to effectively combat plant defense reactions. These results furthermore substantiated our *in vitro* findings and showed that AcrB and TolC of *E. coli* and *E. amylovora* are apparently fully interchangeable. The herein obtained data are in line with recent findings of Krishnamoorthy *et al*. \[[@b49-ijms-10-00629]\], who reported that the replacement of *E. coli* AcrB with its close homolog, MexB, from *Pseudomonas aeruginosa* formed a partially functional MDE system, AcrA-MexB-TolC, *in vitro* and that certain single amino acid substitutions in AcrA and MexB, respectively, were sufficient to render this MDE hybrid fully functional. The data obtained herein demonstrated that complementation of *acrAB* or *tolC* of a plant pathogen by respective alleles derived from *E. coli* can restore full virulence. In this respect, our results are in advancement towards those of Brown *et al*. \[[@b32-ijms-10-00629]\], who had demonstrated that MDE components of the plant pathogen *R. solanacearum* were successfully complementing *E. coli* mutants *in vitro*.

3.. Experimental
================

3.1.. Bacterial strains, plasmids, and growth conditions
--------------------------------------------------------

Bacterial strains and plasmids used in this study were listed in [Tables 5](#t5-ijms-10-00629){ref-type="table"} and [6](#t6-ijms-10-00629){ref-type="table"}. *E. coli* strains were routinely maintained at 37°C on Luria-Bertani (LB) medium, and *E. amylovora* strains were cultured at 28 °C on LB medium or asparagine minimal medium 2 (AMM2).

AMM2 has the following composition (per liter of deionized water): fructose, 10 g; [l]{.smallcaps}-asparagine, 4 g; Na~2~HPO~4~ × 7 H~2~O, 12.8 g; K~2~HPO~4~, 3 g; NaCl, 3 g; MgSO~4~ × 7 H~2~O, 0.2 g; nicotinic acid, 0.25 g; thiamine, 200 μg. *E. coli* DH5α was used as cloning host. Cultures were supplemented with 50 μg/mL ampicillin (Ap), 25 μg/mL chloramphenicol (Cm), 2 μg/mL gentamycin (Gm), and 25 μg/mL kanamycin (Km) when necessary. Bacterial growth was monitored using a spectrophotometer (OD at 600 nm).

3.2.. Generation of tolC mutants in E. coli
-------------------------------------------

*E. coli tolC*-deficient mutants TG1-1 and KAM3-1 were generated by marker exchange mutagenesis as follows. An 1851-bp fragment located in the *tolC* gene was PCR-amplified from *E. coli* TG1 using primer pair Ec-tolC-del-Fwd and Ec-tolC-del-Rev ([Table 7](#t7-ijms-10-00629){ref-type="table"}). The PCR product was cloned into pGEM-T Easy (Promega, Mannheim, Germany) yielding plasmid pNK14. A 597-bp *Bss*HII fragment of pNK14 located in the *tolC* gene was replaced by a 1246-bp *Bss*HII fragment containing the gentamycin resistance cassette (Gm^r^) derived from pBBR1MCS-5 \[[@b52-ijms-10-00629]\] yielding the 5515-bp plasmid pNK15. A 2500-bp *Eco*RI fragment cut from pNK15 was ligated into *Eco*RI-digested pCAM-MCS \[[@b33-ijms-10-00629]\] yielding the final *tolC* replacement plasmid pNK16 (6207 bp). *E. coli* S17-1 *λ-pir* was used as host for the suicide plasmid. Plasmid pNK16 was transferred via electroporation into electro-competent cells of *E. coli* TG1 and its *acrB* mutant KAM3, which subsequently were grown at 37°C for 1 h in SOC broth and plated on LB containing gentamycin. Putative mutants were screened for homologous recombination events by checking their antibiotics resistance. To confirm the altered genotypes, PCR amplification of *tolC* using primers Ec-tolC-del-Fwd and Ec-tolC-del-Rev ([Table 7](#t7-ijms-10-00629){ref-type="table"}) was carried out yielding a 2500-bp fragment for the *tolC* mutants as opposed to the presence of an 1851-bp fragment for the wild type.

3.3.. Complementation of mutants
--------------------------------

The plasmid for complementation of the *tolC*-deficient *E. coli* was generated as follows: a 2012-bp fragment containing the *tolC* region was PCR amplified from *E. coli* TG1 using primer pair Ec-tolC-com-Fwd and Ec-tolC-com-Rev ([Table 7](#t7-ijms-10-00629){ref-type="table"}). The PCR fragment was cloned into *Spe*I-*Sac*I-digested pBBR1MCS \[[@b52-ijms-10-00629]\] yielding the *E. coli tolC* complementation plasmid pNK17 (6719 bp). Plasmid pNK7 \[[@b34-ijms-10-00629]\] was used to complement the *tolC* mutant of *E. amylovora*.

The plasmids for complementation of the *acrAB*- and *acrABR*-deficient *E. coli* mutants were generated as follows: 4701-bp and 5596-bp fragments containing the *acrAB* and *acrAB-R* regions, respectively, were PCR amplified from *E. coli* TG1 using the primer pairs Ec-acr-com-Fwd/Ec-acr-com-Rev- and Ec-acr-com-Fwd/Ec-acr-com-Rev+ ([Table 7](#t7-ijms-10-00629){ref-type="table"}). The PCR fragments were cloned into *Hind*III-*Sac*I-digested pBBR1MCS \[[@b52-ijms-10-00629]\] yielding the *E. coli acrAB* complementation plasmid pNK18 (9408 bp) and the *E.coli acrAB-R* complementation plasmid pNK19 (10303 bp).

The plasmid for complementation of the *acrABR*-deficient *E. amylovora* mutant was generated as follows: a 5746-bp fragment containing the *acrAB-R* region was PCR amplified from *E. amylovora* 1189 using the primer pair Ea-acr-Com-Fwd+ and Ea-acr-Com-Rev ([Table 7](#t7-ijms-10-00629){ref-type="table"}). The PCR fragment was cloned into *Spe*I-*Sac*I digested pBBR1MCS \[[@b52-ijms-10-00629]\] yielding the *E. amylovora acrAB-R* complementation plasmid pNK20 (10453 bp). Plasmid pNK8 \[[@b34-ijms-10-00629]\] was used to complement the *acrB* mutant of *E. amylovora*.

3.4.. Drug susceptibility tests
-------------------------------

The minimal inhibitory concentrations (MIC) were determined by a twofold dilution assay in Mueller-Hinton broth (MHB) (Becton Dickinson, Heidelberg, Germany) and AMM2, respectively. All tests were done in triplicate following the National Center for Clinical Laboratory Standards recommendations \[[@b53-ijms-10-00629]\]. Chemicals were obtained from Sigma-Aldrich (Taufkirchen, Germany). *E. amylovora* strains were incubated at 28 °C, and *E. coli* strains were incubated at 37 °C. The MIC was defined as the lowest concentration of an antibiotic that completely stopped visible cell growth. Bacterial growth was examined by visual and photometric inspection after 24 h of incubation.

3.5.. Plant materials and pathogenicity assay on apple
------------------------------------------------------

Apple plants (rootstock Malus MM106) were grown in a light chamber at 20 to 25 °C, 60% humidity, with a 12-h photoperiod (15,000 lux). *E. amylovora* strains were grown on LB agar plates for 48 h, re-suspended in sterile 0.9% NaCl solution, and diluted to a cell density of 1 x 10^7^ CFU/mL for inoculation. Apple plants were inoculated by the prick technique as described previously \[[@b48-ijms-10-00629]\]. Each bacterial strain was inoculated into shoots of five individual plants by placing 5 μL of bacterial suspensions onto each wound on the shoot tip. The experiment was repeated three-fold. Plants were monitored for symptom development daily.

4.. Conclusions
===============

The AcrAB-TolC system is widely distributed among Gram-negative bacteria and represents a bacterial defense system not only against antibiotics, but also against numerous structurally unrelated molecules present in different ecological niches, such as bile salt in the intestinal tract and phytoalexins in plants. Herein it was demonstrated that components of the MDE system, AcrAB-TolC, of two different enterobacterial species are interchangeable despite of the significantly diverse ecological niches, in which both species live. On one hand, this might reflect the broad flexibility of this important bacterial antibiotics resistance determinant. On the other hand, these results suggested that habitat-borne divergence of antibiotics exposure did not lead to significant structural modifications of this MDE system during evolution. For the first time, it was demonstrated that respective *E. coli* genes can restore full virulence to *E. amylovora* mutants defective in the genes encoding for AcrAB-TolC.

This project was partially funded by a stipend from the Deutscher Akademischer Austauschdienst (DAAD).

![Pathogenicity assay on apple plants. Shoot tips were inoculated with 5 μL of 1 x 10^7^ CFU/mL bacterial suspensions. Disease symptoms such as the typical 'shepherd's crook' formation and wilting developed on plants inoculated with *E. amylovora* wild type after one week of inoculation.](ijms-10-00629f1){#f1-ijms-10-00629}

###### 

Susceptibility of *Escherichia coli* strains to different compounds in complex medium MHB.

  Compounds          MIC*[a](#tfn1-ijms-10-00629){ref-type="table-fn"}* (μg/mL)                                                      
  ------------------ ------------------------------------------------------------ ------- ------- ------- -------- -------- -------- --------
  Phloretin          \>1000                                                       250     125     125     \>1000   \>1000   \>1000   \>1000
  Naringenin         \>1000                                                       125     125     125     \>1000   \>1000   \>1000   \>1000
  (+)-Catechin       \>1000                                                       250     250     250     \>1000   \>1000   \>1000   \>1000
  Quercetin          \>1000                                                       125     62.5    62.5    \>1000   \>1000   \>1000   \>1000
  Berberine          \>1000                                                       62.5    62.5    62.5    \>1000   \>1000   \>1000   \>1000
  Bile salt          \>1000                                                       15.6    15.6    15.6    \>1000   \>1000   \>1000   \>1000
                                                                                                                                     
  Acriflavine        15.6                                                         1.56    1.56    1.56    31.2     31.2     15.6     15.6
  Novobiocin         1000                                                         50      50      25      \>1000   \>1000   1000     1000
  Ampicillin         31.2                                                         6.25    6.25    6.25    31.2     31.2     31.2     31.2
  Cefoperazone       12.5                                                         0.75    0.75    0.75    6.25     6.25     6.25     12.5
  Mitomycin          50                                                           2.5     1.25    1.25    50       100      50       50
  Tetracycline       3.12                                                         0.15    0.075   0.075   3.12     3.12     3.12     3.12
  Nalidixic acid     10                                                           1       1       1       10       10       5        10
  Norfloxacin        0.62                                                         0.062   0.062   0.062   0.62     0.62     0.62     1.25
  Ciprofloxacin      0.62                                                         0.062   0.062   0.062   0.62     0.62     0.62     0.62
  Amikacin           1.25                                                         1.25    0.15    0.15    1.25     1.25     2.5      1.25
  Tobramycin         2.5                                                          1.25    0.15    0.075   2.5      5        5        5
  Erythromycin       12.5                                                         3.12    0.62    0.15    12.5     25       25       12.5
  Rifampin           12.5                                                         1.56    0.31    0.075   25       25       12.5     25
  Jasmone            500                                                          125     31.2    7.5     500      1000     1000     250
  Clotrimazole       62.5                                                         6.25    1.56    0.31    62.5     31.2     31.2     62.5
                                                                                                                                     
  SDS                1000                                                         100     100     100     1000     1000     1000     1000
  Ethidium bromide   250                                                          15.6    15.6    15.6    250      500      125      250
  Crystal violet     12.5                                                         2.5     2.5     2.5     12.5     25       12.5     12.5

MIC determination by the dilution assay was repeated at least three times in each case thereby confirming consistencies of MIC values.

###### 

Susceptibility of *Erwinia amylovora* strains to different compounds in complex medium MHB.

  Compounds          MIC*[a](#tfn2-ijms-10-00629){ref-type="table-fn"}*(μg/mL)                                                      
  ------------------ ----------------------------------------------------------- ------- ------- ------- -------- -------- -------- --------
  Phloretin          1000                                                        125     125     125     \>1000   \>1000   \>1000   \>1000
  Naringenin         1000                                                        62.5    125     125     1000     1000     1000     1000
  (+)-Catechin       \>1000                                                      125     250     250     \>1000   \>1000   \>1000   \>1000
  Quercetin          1000                                                        62.5    62.5    125     \>1000   \>1000   1000     1000
  Berberine          1000                                                        31.2    31.2    31.2    1000     1000     1000     1000
  Bile salt          \>1000                                                      125     125     125     \>1000   \>1000   \>1000   \>1000
                                                                                                                                    
  Acriflavine        15.6                                                        1.56    3.12    3.12    31.2     31.2     31.2     31.2
  Novobiocin         62.5                                                        1.56    1.56    1.56    62.5     31.2     62.5     62.5
  Ampicillin         62.5                                                        6.25    12.5    6.25    62.5     62.5     62.5     31.2
  Cefoperazone       12.5                                                        3.12    3.12    3.12    12.5     25       12.5     12.5
  Mitomycin          6.25                                                        0.31    0.62    0.62    12.5     25       12.5     12.5
  Tetracycline       6.25                                                        0.62    0.62    0.62    12.5     6.25     6.25     12.5
  Nalidixic acid     1.25                                                        0.12    0.12    0.12    1.25     0.62     1.25     1.25
  Norfloxacin        0.62                                                        0.031   0.062   0.062   0.62     0.62     0.62     0.62
  Ciprofloxacin      0.62                                                        0.062   0.062   0.062   0.62     0.62     0.62     0.62
  Amikacin           2.5                                                         2.5     0.31    0.31    1.25     1.25     2.5      1.25
  Tobramycin         2.5                                                         1.25    0.075   0.15    2.5      2.5      2.5      5
  Erythromycin       12.5                                                        3.12    0.62    0.15    12.5     25       25       12.5
  Rifampin           12.5                                                        3.12    0.31    0.075   25       12.5     12.5     25
  Jasmone            250                                                         62.5    15.6    3.12    250      250      500      500
  Clotrimazole       15.6                                                        3.12    0.15    0.075   62.5     31.2     62.5     31.2
                                                                                                                                    
  SDS                \>1000                                                      100     100     100     \>1000   \>1000   1000     1000
  Ethidium bromide   31.2                                                        3.12    3.12    3.12    62.5     62.5     62.5     62.5
  Crystal violet     3.12                                                        0.62    0.62    0.62    3.12     3.12     3.12     6.25

MIC determination by the dilution assay was repeated at least three times in each case thereby confirming consistencies of MIC values.

###### 

Susceptibility of *Escherichia coli* strains to different compounds in minimal medium AMM2.

  Compounds          MIC *[a](#tfn3-ijms-10-00629){ref-type="table-fn"}* (μg/mL)                                                      
  ------------------ ------------------------------------------------------------- ------- ------- ------- -------- -------- -------- --------
  Phloretin          \>1000                                                        250     125     250     \>1000   \>1000   \>1000   \>1000
  Naringenin         \>1000                                                        125     250     125     \>1000   \>1000   \>1000   \>1000
  (+)-Catechin       \>1000                                                        125     125     62.5    \>1000   \>1000   \>1000   \>1000
  Quercetin          \>1000                                                        125     125     62.5    \>1000   \>1000   \>1000   \>1000
  Berberine          \>1000                                                        62.5    62.5    62.5    \>1000   \>1000   \>1000   \>1000
  Bile salt          \>1000                                                        15.6    15.6    15.6    \>1000   \>1000   \>1000   \>1000
                                                                                                                                      
  Acriflavine        7.5                                                           1.56    1.56    1.56    7.5      15.6     7.5      15.6
  Novobiocin         1000                                                          100     100     50      \>1000   \>1000   \>1000   1000
  Ampicillin         15.6                                                          3.12    6.25    3.12    31.2     31.2     31.2     31.2
  Cefoperazone       6.25                                                          0.62    0.62    0.62    6.25     6.25     6.25     12.5
  Mitomycin          12.5                                                          1.5     1.5     1.5     12.5     12.5     12.5     12.5
  Tetracycline       1.56                                                          0.15    0.15    0.075   1.56     1.56     3.12     3.12
  Nalidixic acid     6.25                                                          1.25    0.62    0.62    12.5     6.25     12.5     12.5
  Norfloxacin        0.62                                                          0.062   0.062   0.062   0.62     0.62     0.62     1.25
  Ciprofloxacin      0.62                                                          0.015   0.062   0.062   0.62     0.62     0.62     0.62
  Amikacin           1.25                                                          1.25    0.15    0.075   1.25     1.25     2.5      1.25
  Tobramycin         1.25                                                          1.25    0.075   0.075   2.5      5        5        5
  Erythromycin       25                                                            3.12    0.62    0.15    12.5     25       12.5     12.5
  Rifampin           12.5                                                          1.56    0.31    0.075   25       25       12.5     25
  Jasmone            500                                                           125     31.2    7.5     1000     500      1000     500
  Clotrimazole       62.5                                                          6.25    1.56    0.31    125      62.5     125      62.5
                                                                                                                                      
  SDS                500                                                           100     100     100     500      500      500      1000
  Ethidium bromide   125                                                           1.56    1.56    1.56    250      250      125      250
  Crystal violet     6.25                                                          1.25    0.62    0.62    6.25     6.25     6.25     12.5

MIC determination by the dilution assay was repeated at least three times in each case thereby confirming consistencies of MIC values.

###### 

Susceptibility of *Erwinia amylovora* strains to different compounds in minimal medium AMM2.

  Compounds          MIC*[a](#tfn4-ijms-10-00629){ref-type="table-fn"}*(μg/mL)                                                      
  ------------------ ----------------------------------------------------------- ------- ------- ------- -------- -------- -------- --------
  Phloretin          1000                                                        125     125     125     \>1000   \>1000   \>1000   \>1000
  Naringenin         1000                                                        62.5    125     125     1000     1000     1000     1000
  (+)-Catechin       \>1000                                                      125     250     250     \>1000   \>1000   \>1000   \>1000
  Quercetin          1000                                                        62.5    62.5    125     \>1000   \>1000   1000     1000
  Berberine          1000                                                        31.2    31.2    31.2    1000     1000     1000     1000
  Bile salt          \>1000                                                      125     125     125     \>1000   \>1000   \>1000   \>1000
                                                                                                                                    
  Acriflavine        15.6                                                        1.56    3.12    3.12    31.2     31.2     31.2     31.2
  Novobiocin         62.5                                                        1.56    1.56    1.56    62.5     31.2     62.5     62.5
  Ampicillin         62.5                                                        6.25    12.5    6.25    62.5     62.5     62.5     31.2
  Cefoperazone       12.5                                                        3.12    3.12    3.12    12.5     25       12.5     12.5
  Mitomycin          6.25                                                        0.31    0.62    0.62    12.5     25       12.5     12.5
  Tetracycline       6.25                                                        0.62    0.62    0.62    12.5     6.25     6.25     12.5
  Nalidixic acid     1.25                                                        0.12    0.12    0.12    1.25     0.62     1.25     1.25
  Norfloxacin        0.62                                                        0.031   0.062   0.062   0.62     0.62     0.62     0.62
  Ciprofloxacin      0.62                                                        0.062   0.062   0.062   0.62     0.62     0.62     0.62
  Amikacin           1.25                                                        1.25    0.075   0.075   1.25     2.5      1.25     1.25
  Tobramycin         2.5                                                         2.5     0.15    0.15    2.5      2.5      2.5      2.5
  Erythromycin       25                                                          6.25    1.25    0.31    12.5     25       12.5     12.5
  Rifampin           6.25                                                        1.56    0.15    0.075   25       25       12.5     25
  Jasmone            125                                                         31.2    7.5     1.56    250      250      250      250
  Clotrimazole       31.2                                                        6.25    3.12    0.31    62.5     31.2     31.2     62.5
                                                                                                                                    
  SDS                \>1000                                                      100     100     100     \>1000   \>1000   1000     1000
  Ethidium bromide   31.2                                                        3.12    3.12    3.12    62.5     62.5     62.5     62.5
  Crystal violet     3.12                                                        0.62    0.62    0.62    3.12     3.12     3.12     6.25

MIC determination by the dilution assay was repeated at least three times in each case thereby confirming consistencies of MIC values.

###### 

*E. coli* and *E. amylovora* strains used in this study.

  Strain           Relevant characteristics                                                          Reverence or source
  ---------------- --------------------------------------------------------------------------------- ---------------------------------------------------
  *E. coli*                                                                                          \[[@b42-ijms-10-00629]\]
  DH5α             *supE*44 Δ*lac*U169 (φ80 *lacZ* ΔM15) *hsdR*17 *recA*1 *endA*1 *gyrA*96 *thi*-1   
  S17-1 *λ-pir*    *λ-pir* lysogen of S17-1                                                          \[[@b50-ijms-10-00629]\]
  TG1              *subE hsd*Δ5 *thi* Δ(*lac-proAB*) F\`\[*traD*36 *proAB*^+^*lacI^q^lacZ*ΔM15\]     \[[@b42-ijms-10-00629]\]
  KAM3             *acrB* mutant of TG1                                                              \[[@b51-ijms-10-00629]\]
  TG1-1            Gm^r^, *tolC* mutant of TG1                                                       This study
  KAM3-1           Gm^r^, *tolC* mutant of KAM3                                                      This study
  *E. amylovora*                                                                                     
  1189             wild type                                                                         GSPB[a](#tfn5-ijms-10-00629){ref-type="table-fn"}
  1189-3           Km^r^, *acrB* mutant of 1189                                                      \[[@b33-ijms-10-00629]\]
  1189-25          Gm^r^, *tolC* mutant of 1189                                                      \[[@b34-ijms-10-00629]\]
  1189-3-3         Km^r^, Gm^r^, *acrB tolC* mutant of 1189                                          \[[@b34-ijms-10-00629]\]

GSPB, Göttinger Sammlung phytopathogener Bakterien, Göttingen, Germany.

###### 

Plasmids used in this study.

  Plasmid       Relevant characteristics                                                                                                                             Reference or source
  ------------- ---------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------
  pGEM-T Easy   Ap^r^, ColE1 origin                                                                                                                                  Promega
  pNK14         Ap^r^, 1851-bp PCR fragment containing *E. coli tolC* in pGEM-T Easy                                                                                 This study
  pBBR1MCS-5    Gm^r^, Source of the Gm^r^ cassette                                                                                                                  \[[@b52-ijms-10-00629]\]
  pNK15         Ap^r^, replacement of a 597-bp BssHII fragment from the *tolC* gene of pNK14 with a 1246-bp fragment containing the Gm^r^ cassette from pBBR1MCS-5   This study
  pCAM-MCS      Ap^r^, pCAM140-derivative without mini-Tn5, contains the MCS of pBluescript II SK (+)                                                                \[[@b33-ijms-10-00629]\]
  pNK16         Ap^r^, Gm^r^, 2500-bp EcoRI fragment from pNK15 ligated into EcoRI-linearized pCAM-MCS                                                               This study
  pBBR1MCS      Cm^r^, ColE1 origin                                                                                                                                  \[[@b52-ijms-10-00629]\]
  pNK17         Cm^r^, 2012-bp SpeI-SacI fragment carrying *tolC* of *E. coli* cloned in pBBR1MCS in opposite direction of *lacZ*                                    This study
  pNK18         Cm^r^, 4701-bp HindIII-SacI fragment carrying *acrAB* of *E. coli* cloned in pBBR1MCS in opposite direction of *lacZ*                                This study
  pNK19         Cm^r^, 5596-bp HindIII-SacI fragment carrying *acrAB-R* of *E. coli* cloned in pBBR1MCS in opposite direction of *lacZ*                              This study
  pNK7          Cm^r^, 2630 bp SpeI-SacII fragment carrying *tolC* of *E. amylovora* cloned in pBBR1MCS in opposite direction of *lacZ*                              \[[@b34-ijms-10-00629]\]
  pNK8          Cm^r^, 4917 bp SpeI-SacI fragment carrying *acrAB* of *E. amylovora* cloned in pBBR1MCS in opposite direction of *lacZ*                              \[[@b34-ijms-10-00629]\]
  pNK20         Cm^r^, 5746 bp SpeI-SacI fragment carrying *acrAB-R* of *E. amylovora* cloned in pBBR1MCS in opposite direction of *lacZ*                            This study

###### 

Oligonucleotide primers used in this study.

  Primer            Nucleotide sequence (5\'--3\')[\*](#tfn6-ijms-10-00629){ref-type="table-fn"}
  ----------------- ------------------------------------------------------------------------------
  Ec-tolC-del-Fwd   AACTTCATCACGCACTGG
  Ec-tolC-del-Rev   TTGCTGAACGACTGGTGC
  Ec-tolC-com-Fwd   GAT[GAGCTC]{.ul}AACTTCATCACGCACTGG
  Ec-tolC-com-Rev   CGA[ACTAGT]{.ul}ATAGAGGATGGCTGGTCG
  Ec-acr-com-Fwd    CGAT[AAGCTT]{.ul}GAGATCCTGAGTTGGTGG
  Ec-acr-com-Rev-   GCTA[GAGCTC]{.ul}AGCGAGGTGGATGATACC
  Ec-acr-com-Rev+   GCTA[GAGCTC]{.ul}GTATCTGTCAGATCCTGC
  Ea-acr-com-Fwd+   CGA[GAGCTC]{.ul}GAATACGGTTCTCTGAGC
  Ea-acr-com-Rev    GAT[ACTAGT]{.ul}CGGTATAGTAAACGTGCG

Restriction sites incorporated into primers are underlined: AAGCTT, *Hind*III; GAGCTC, *Sac*I; and ACTAGT, *Spe*I.
